Clinical Trial Update: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating a quadruplet combination of isatuximab, lenalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Revlimid (lenalidomide)
• SARCLISA (isatuximab)
• Velcade (bortezomib)

Snippet

Sponsor: Jacob Laubach, MD | Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) | Phase 2 | Status: ACTIVE_NOT_RECRUITING